Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
ABSTRACT Nutritional iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral iron supplementation is usually the first choice for the treatment of iron deficiency anemia, but in many conditions, oral iron is less than ideal mainly because of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-12-01
|
| Series: | Revista Brasileira de Hematologia e Hemoterapia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600400&lng=en&tlng=en |
| _version_ | 1828531770814889984 |
|---|---|
| author | João Ricardo Friedrisch Rodolfo Delfini Cançado |
| author_facet | João Ricardo Friedrisch Rodolfo Delfini Cançado |
| author_sort | João Ricardo Friedrisch |
| collection | DOAJ |
| description | ABSTRACT Nutritional iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral iron supplementation is usually the first choice for the treatment of iron deficiency anemia, but in many conditions, oral iron is less than ideal mainly because of gastrointestinal adverse events and the long course needed to treat the disease and replenish body iron stores. Intravenous iron compounds consist of an iron oxyhydroxide core, which is surrounded by a carbohydrate shell made of polymers such as dextran, sucrose or gluconate. The first iron product for intravenous use was the high molecular weight iron dextran. However, dextran-containing intravenous iron preparations are associated with an elevated risk of anaphylactic reactions, which made physicians reluctant to use intravenous iron for the treatment of iron deficiency anemia over many years. Intravenous ferric carboxymaltose is a stable complex with the advantage of being non- dextran-containing and a very low immunogenic potential and therefore not predisposed to anaphylactic reactions. Its properties permit the administration of large doses (15 mg/kg; maximum of 1000 mg/infusion) in a single and rapid session (15-minute infusion) without the requirement of a test dose. The purpose of this review is to discuss some pertinent issues in relation to the history, pharmacology, administration, efficacy, and safety profile of ferric carboxymaltose in the treatment of patients with iron deficiency anemia. |
| first_indexed | 2024-12-11T22:42:44Z |
| format | Article |
| id | doaj.art-13f1992ca314486bbe4914c6312a2412 |
| institution | Directory Open Access Journal |
| issn | 1806-0870 |
| language | English |
| last_indexed | 2024-12-11T22:42:44Z |
| publishDate | 2015-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Revista Brasileira de Hematologia e Hemoterapia |
| spelling | doaj.art-13f1992ca314486bbe4914c6312a24122022-12-22T00:47:44ZengElsevierRevista Brasileira de Hematologia e Hemoterapia1806-08702015-12-0137640040510.1016/j.bjhh.2015.08.012S1516-84842015000600400Intravenous ferric carboxymaltose for the treatment of iron deficiency anemiaJoão Ricardo FriedrischRodolfo Delfini CançadoABSTRACT Nutritional iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral iron supplementation is usually the first choice for the treatment of iron deficiency anemia, but in many conditions, oral iron is less than ideal mainly because of gastrointestinal adverse events and the long course needed to treat the disease and replenish body iron stores. Intravenous iron compounds consist of an iron oxyhydroxide core, which is surrounded by a carbohydrate shell made of polymers such as dextran, sucrose or gluconate. The first iron product for intravenous use was the high molecular weight iron dextran. However, dextran-containing intravenous iron preparations are associated with an elevated risk of anaphylactic reactions, which made physicians reluctant to use intravenous iron for the treatment of iron deficiency anemia over many years. Intravenous ferric carboxymaltose is a stable complex with the advantage of being non- dextran-containing and a very low immunogenic potential and therefore not predisposed to anaphylactic reactions. Its properties permit the administration of large doses (15 mg/kg; maximum of 1000 mg/infusion) in a single and rapid session (15-minute infusion) without the requirement of a test dose. The purpose of this review is to discuss some pertinent issues in relation to the history, pharmacology, administration, efficacy, and safety profile of ferric carboxymaltose in the treatment of patients with iron deficiency anemia.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600400&lng=en&tlng=enAnemiaIron-deficiencyTherapeuticsAnemia |
| spellingShingle | João Ricardo Friedrisch Rodolfo Delfini Cançado Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia Revista Brasileira de Hematologia e Hemoterapia Anemia Iron-deficiency Therapeutics Anemia |
| title | Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia |
| title_full | Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia |
| title_fullStr | Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia |
| title_full_unstemmed | Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia |
| title_short | Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia |
| title_sort | intravenous ferric carboxymaltose for the treatment of iron deficiency anemia |
| topic | Anemia Iron-deficiency Therapeutics Anemia |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600400&lng=en&tlng=en |
| work_keys_str_mv | AT joaoricardofriedrisch intravenousferriccarboxymaltoseforthetreatmentofirondeficiencyanemia AT rodolfodelfinicancado intravenousferriccarboxymaltoseforthetreatmentofirondeficiencyanemia |